A Literature Review of Genetic Markers Conferring Impaired Response to Cardiovascular Drugs

Am J Cardiovasc Drugs. 2018 Aug;18(4):259-269. doi: 10.1007/s40256-018-0267-2.

Abstract

Pharmacogenetics is an emerging area of medicine, and more work is needed to fully integrate it into a clinical setting for the benefit of patients. Genetic markers can influence the action of many drugs, including those that prevent and treat cardiovascular conditions. Genotyping is not yet commonplace, but guidelines are being put in place to help practitioners determine the effect a genetic marker may have on certain drugs. With advancements in genetic technology and falling costs, genotyping could be available to all patients via a simple saliva test. This would be a cost-effective way for practitioners to determine the most effective treatment for individuals, reducing "trial and error," adverse effects, and rehospitalization rates and increasing patient compliance. Cardiovascular diseases are the leading causes of death worldwide, so using the most effective medication to treat or prevent them is of utmost importance in reducing incidence and mortality.

Publication types

  • Review

MeSH terms

  • Cardiovascular Agents / therapeutic use*
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / etiology*
  • Cost-Benefit Analysis / methods
  • Genetic Markers / genetics*
  • Humans
  • Pharmacogenetics / methods

Substances

  • Cardiovascular Agents
  • Genetic Markers